Analysts expect ARS Pharmaceuticals, Inc. to report revenue of 40.48 M for Q3 26, against a range of 38.27 M to 42.69 M. The most recent reported quarter, Q2 26, came in at 33.66 M, a 10.6% beat against the 30.44 M consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 2.07 M | 86.60 M | 7.97 M | 15.72 M | 32.50 M | 28.10 M | 22.68 M | 33.66 M | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 565,523.82 | 6.41 M | 8.33 M | 14.62 M | 27.80 M | 25.34 M | 23.70 M | 31.96 M | 42.69 M | 30.26 M | 31.86 M | 44.80 M | 59.43 M | 53.01 M | 50.47 M | 80.11 M | ||||||||||
| Low Estimate | 519,943.94 | 5.41 M | 7.02 M | 13.58 M | 26.07 M | 23.25 M | 21.75 M | 28.91 M | 38.27 M | 27.31 M | 26.36 M | 39.29 M | 53.40 M | 44.32 M | 43.98 M | 74.53 M | ||||||||||
| Consensus Estimate | 542,733.88 | 5.91 M | 7.67 M | 14.10 M | 26.93 M | 24.30 M | 22.72 M | 30.44 M | 40.48 M | 28.78 M | 29.11 M | 42.05 M | 56.41 M | 48.66 M | 47.23 M | 77.32 M |
Analysts expect ARS Pharmaceuticals, Inc. to report earnings per share of -0.29 for Q3 26, against a range of -0.31 to -0.27. The most recent reported quarter, Q2 26, came in at -0.63, a 37.0% miss against the -0.46 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.20 | 0.48 | -0.35 | -0.46 | -0.52 | -0.41 | -0.61 | -0.63 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -0.14 | -0.21 | -0.30 | -0.41 | -0.44 | -0.41 | -0.52 | -0.42 | -0.27 | -0.28 | -0.34 | -0.21 | -0.12 | -0.11 | -0.18 | -0.05 | ||||||||||
| Low Estimate | -0.14 | -0.25 | -0.36 | -0.47 | -0.50 | -0.49 | -0.56 | -0.50 | -0.31 | -0.32 | -0.40 | -0.23 | -0.12 | -0.13 | -0.20 | -0.05 | ||||||||||
| Consensus Estimate | -0.14 | -0.23 | -0.33 | -0.44 | -0.47 | -0.45 | -0.54 | -0.46 | -0.29 | -0.30 | -0.37 | -0.22 | -0.12 | -0.12 | -0.19 | -0.05 |
Pull Wall Street consensus for ARS Pharmaceuticals, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=SPRY&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "SPRY", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=SPRY&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();